Oncotype Dx Breast Cancer Assay in Older Patients: A Real Life Cohort
Cancer Medicine · 2025-11 · 14 (22)
DOI: 10.1002/cam4.71386 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 20.11.2025. Verfasst von Clément Grosnon und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Institut Universitaire de Cancérologie AP-HP Sorbonne Université, Tenon Hospital, Paris, France. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm Recurrence, Local, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The Oncotype DX Breast Recurrence Score test was designed for HR+, HER2− early breast cancer (eBC) to assist in the decision‐making process for de‐escalating adjuvant chemotherapy (CT). Its validity and utility have been demonstrated prospectively across multiple studies, though data on older patients remain limited.
Methods
This prospective cohort study included patients over 70 years with eBC treated between 2018 and 2023 at Tenon Hospital, Paris, France. Characteristics of populations eligible for the test and those with RS ≤ or > 25 were collected, along with oncogeriatric assessment and treatments; statistical analysis was performed for IDFS and OS.
Results
Of the 365 patients > 70 years, mean age was 77.6 years (range 70–96), with 84.4% diagnosed with HR+/HER2− eBC. Oncotype DX testing was performed in 85 patients (27.9% of HR+/HER2− eBC), revealing a Recurrence Score (RS) result > 25 in 14 patients (15%). The RS > 25 group had more grade 3 tumors, more pT2 tumors, and a higher Ki67 > 20%. In the RS > 25 group, 9 patients (64%) had oncogeriatric consultations, and 7 (50%) started the recommended adjuvant CT. Four patients received taxane‐cyclophosphamide (TC) and 3 adriamycin‐cyclophosphamide‐taxane (AC‐T), with 2 discontinuing due to taxane‐induced neuropathy. Median IDFS was significantly lower in the RS > 25 group ( p = 0.0023), with 4 of 5 recurrences occurring in patients who did not receive adjuvant CT. OS showed no significant difference by RS group ( p = 0.87).
Conclusion
This observational study highlights that the Oncotype DX test supports therapeutic de‐escalation in patients with RS ≤ 25 and serves as a prognostic marker. Oncogeriatric evaluations are essential to guide adjuvant treatments in older breast cancer patients prior to using genomic signatures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Department, Institut Universitaire de Cancérologie AP-HP Sorbonne Université, Tenon Hospital, Paris, France.
- Gynaecology Department, Institut Universitaire de Cancérologie AP-HP Sorbonne Université, Tenon Hospital, Paris, France.
- Anatomopathology Department, Institut Universitaire de Cancérologie AP-HP Sorbonne Université, Tenon Hospital, Paris, France.
ORCID-Profile: Clément Grosnon, Joseph Gligorov, Marc-Antoine Benderra
Zitieren
APA
Grosnon, C., Seknazi, L., Ghebriou, D., Sabaila, A., Buob, D., Nedelcu, M., Le Gac, M., Jamelot, M., Prebet, C., Lotz, J. P., Gligorov, J., & Benderra, M. A. (2025). Oncotype Dx Breast Cancer Assay in Older Patients: A Real Life Cohort. Cancer Medicine, 14(22). https://doi.org/10.1002/cam4.71386
Vancouver
Grosnon C, Seknazi L, Ghebriou D, Sabaila A, Buob D, Nedelcu M, et al. Oncotype Dx Breast Cancer Assay in Older Patients: A Real Life Cohort. Cancer Medicine. 2025;14(22). doi:10.1002/cam4.71386
BibTeX
@article{Grosnon2025,
author = {Grosnon, Clément and Seknazi, Lauren and Ghebriou, Djamel and Sabaila, Anne and Buob, David and Nedelcu, Mariana and Le Gac, Marjolaine and Jamelot, Mathieu and Prebet, Coralie and Lotz, Jean-Pierre and Gligorov, Joseph and Benderra, Marc-Antoine},
title = {Oncotype Dx Breast Cancer Assay in Older Patients: A Real Life Cohort},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {22},
doi = {10.1002/cam4.71386}
}
EUVIMED